Cancer Biomarkers

The Cancer Biomarkers Research Group (CBRG) promotes research to identify, develop, and validate biological markers for early cancer detection and cancer risk assessment. Activities include development and validation of promising cancer biomarkers, collaborative databases and informatics systems, and new technologies or the refinement of existing technologies.

Read more About the Cancer Biomarkers Research Group.

Staff

Funding Opportunities

Grants

Publications

Alliance of Glycobiologists for Cancer Research

Tumor Glycomics Laboratories work to reveal cancer-related dynamics of complex carbohydrates.

Consortium for Imaging and Biomarkers (CIB)

Research Units integrate imaging strategies with biomarkers to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk, and diagnosis of early stage cancer.

Early Detection Research Network (EDRN)

Labs and centers bring together comprehensive infrastructure and resources critical to discovery, development and validation of biomarkers for cancer risk and early detection.

Liquid Biopsy Consortium

A partnership with academic and industrial laboratory teams developing noninvasive liquid biopsy techniques to detect early stage cancer from biomarkers in blood, urine and sputum.

Pancreatic Cancer Detection Consortium (PCDC)

Research teams develop and test new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma and its precursor lesions.

Translational Liver Cancer (TLC) Consortium

Five Translational Research Centers conduct studies to improve surveillance of liver cancer in high-risk populations, increase detectability at early stages, and stratify at-risk patients.

News and Events